Physician profile
Jerry W Bishop
NPI 1982607875
$2,168.72
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $532 · 2021: $579 · 2022: $301 · 2023: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.00 | 2019-2022 | |
| Amgen INC. | $282.05 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $241.39 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $173.99 | 2021-2023 | Ubrelvy, Qulipta, Vraylar |
| Pfizer INC. | $173.68 | 2019-2023 | |
| Lilly USA, LLC | $136.27 | 2020-2023 | Mounjaro, Jardiance |
| Teleflex LLC | $126.49 | 2023 | Urolift |
| Amarin Pharma, INC. | $112.96 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $112.44 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $77.05 | 2019-2023 | Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $71.98 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $56.54 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $45.49 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $44.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.27 | 2020-2023 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $25.85 | 2020 | |
| Merck Sharp & Dohme LLC | $24.95 | 2021 | |
| Allergan, INC. | $19.38 | 2019 | |
| Medtronic, INC. | $18.26 | 2021 | |
| Abbott Laboratories | $17.91 | 2022 | |
| Almatica Pharma LLC | $15.91 | 2023 | Loreev Xr |
| Eisai INC. | $15.05 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.28 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.